Clinical Trials Logo

Clinical Trial Summary

Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 inhibitor reduces thrombotic events in patients with coronary artery disease, but these benefits come at the expense of increased risk of bleeding when compared with aspirin monotherapy. Increased evidence showed that P2Y12 inhibitor monotherapy still maintain antiischemic efficacy while reducing the bleeding risk compared with DAPT. Therefore, the investigators performed this study to observe the efficacy of ticagrelor in comparison to clopidogrel in Chinese patients with stable CAD.


Clinical Trial Description

Ticagrelor is a novel, direct-acting, reversibly binding P2Y12 receptor antagonist. When related with clopidogrel, ticagrelor exhibits a more potent and more predictable antiplatelet effect with a faster onset and offset of action. Current guidelines give a recommendation on the use of dual antiplatelet therapy support ticagrelor 90 mg twice daily over clopidogrel 75 mg daily in addition to aspirin in CAD patients. However, increasing evidence showed ticagrelor increased the risk of bleeding. Recent studies showed that P2Y12 inhibitor monotherapy still maintain antiischemic efficacy while reducing the bleeding risk compared with DAPT. So the investigators performed this randomized, single-blind, crossover clinical trial to observe the effects of standard-dose ticagrelor and standard-dose clopidogrel on platelet reactivity in Chinese patients with stable CAD. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04001894
Study type Interventional
Source First Affiliated Hospital of Harbin Medical University
Contact
Status Completed
Phase Phase 4
Start date July 2, 2019
Completion date December 9, 2020

See also
  Status Clinical Trial Phase
Not yet recruiting NCT02808039 - Is There a Transient Rebound Effect of Platelet Reactivity Following Cessation of Dual Antiplatelet Therapy With Ticagrelor - a Single Center Prospective Observational Trial N/A
Completed NCT01961856 - Ticagrelor Loading Dose Versus Clopidogrel Loading and Reloading With Ticagrelor. Phase 3
Recruiting NCT03525145 - Platelet Reactivity And Clinical ThrombotIC Events Study
Completed NCT01463163 - Ticagrelor in Comparison to Prasugrel for Early Inhibition of Platelet Reactivity in Patients With ST-elevation Myocardial Infarction (STEMI), Undergoing Primary Percutaneous Coronary Intervention (PCI) Phase 4
Completed NCT01463150 - Prasugrel 5mg Versus High Dose Clopidogrel in Clopidogrel Resistant Patients Aged ≥75 Years and/or Weighing <60 kg Post Percutaneous Coronary Intervention (PCI) Phase 4
Recruiting NCT03614832 - Ticagrelor and Clopidogrel on Platelet Aggregation in Clopidogrel Resistance's Patients With CHD Phase 4
Completed NCT01835353 - High (100mg) Versus Standard (60mg) Loading Dose of Prasugrel in Patients With ST-elevation Myocardial Infarction (STEMI), Undergoing Primary Percutaneous Coronary Intervention (PCI) Phase 3
Recruiting NCT05773989 - Pharmacodynamic Outcomes in CCS Patients Treated With an Individualized Treatment Strategy Phase 4
Completed NCT01511471 - Ticagrelor in Clopidogrel Resistant Patients Undergoing Chronic Hemodialysis Phase 3
Completed NCT00827346 - Platelet Function Monitoring in Patients Treated With Clopidogrel at the Time of Primary Percutaneous Coronary Angioplasty Phase 2/Phase 3
Completed NCT00976196 - Platelet Hyperreactivity Project N/A
Recruiting NCT05367336 - Platelet Reactivity With Fentanyl, Morphine, or no Narcotic Early Phase 1
Completed NCT03679091 - Low-dose of Ticagrelor and Standard-dose Clopidogrel on Platelet Effects in Chinese Patients With Stable CAD. Phase 4
Recruiting NCT05657041 - Body Weight Adjusted Clopidogrel Treatment in Patients With CORonary Artery Disease Phase 2/Phase 3